Pacific Blue Rat Anti-Mouse FOXP3 Antibody (S-R499)

FOXP3 (Forkhead box protein P3) is a 47 kDa transcription factor that acts as the master immune‐suppression switch: it is expressed almost exclusively in CD4⁺ regulatory T (Treg) cells, where it binds to conserved forkhead DNA motifs to repress genes that drive effector T-cell proliferation (e.g., IL-2, IFN-γ) and simultaneously up-regulate genes for inhibitory cytokines (IL-10, TGF-β) and checkpoint molecules (CTLA-4, LAG-3); its N-terminal repressor domain recruits co-repressors such as EZH2 and HDACs, while the C-terminal winged-helix domain mediates DNA contact and homo-multimerization essential for chromatin looping at the IL-2 locus, and mutations in either segment—exemplified by the Δ2 splice variant or the human IPEX mutations p.A384T and p.R397W—abolish DNA binding or nuclear localization, unleashing fatal multi-organ autoimmunity; post-translational control further tunes Treg stability: TCR and IL-2 signals activate PI3K–AKT–mTOR cascades that phosphorylate FOXP3 at S418, enhancing its DNA affinity, whereas inflammatory cytokines like TNF-α and IL-6 trigger PIM1/CK2-mediated phosphorylation at S422 and ubiquitination by STUB1, leading to proteasomal degradation and conversion of Tregs into pro-inflammatory TH17 cells; in cancer, hypoxia-induced HIF-1α and oncogenic STAT3 similarly destabilize FOXP3, weakening intra-tumoral Treg suppressive function and paradoxically enabling immune evasion, whereas demethylating agents or low-dose IL-2 restore FOXP3 expression and are being tested clinically to curb graft-versus-host disease and autoimmunity, making FOXP3 both a biomarker of immune tolerance and a druggable node at the intersection of infection, autoimmunity, and cancer.